4.960USD-0.20%Mkt Cap: 42.71M USDP/E: —Last update: 2026-05-22
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a sele…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap42.71M USD
Enterprise Value11.08M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.77M USD
Revenue/Share—
Last Price4.960 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS04962H5063
Valuation
P/E (Trailing)—
P/E (Forward)-2.04
PEG—
EV/EBITDA-0.28
EV/Revenue—
P/S—
P/B1.40
EPS (TTM)-4.37
EPS (Forward)-2.44
52W Range
3.7608% of range19.35
52W High19.35 USD
52W Low3.760 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-88.35%
ROA-73.03%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.76M USD
CapEx (TTM)23.00K USD
FCF Margin—
FCF Yield-49.71%
Net Debt-31.72M USD
Net Debt/EBITDA0.80
Balance Sheet
Debt/Equity—
Current Ratio4.92
Quick Ratio4.25
Book Value/Sh3.540 USD
Cash/Share3.683 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateApr 20, 2018
Splits
Last Split1:15
Split DateFeb 2, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)22.75 USD
Target Range20.00 USD – 25.00 USD
# Analysts4
Ownership
Shares Out.8.61M
Float8.61M
Insiders1.41%
Institutions18.86%
Short Interest
Short Ratio6.2d
Short % Float3.92%
Short % Out.3.92%
Shares Short337.51K
Short (prev mo.)327.68K
Technical
SMA 505.304 (-6.5%)
SMA 2009.277 (-46.5%)
Beta1.25
S&P 52W Chg28.31%
Avg Vol (30d)54.98K
Avg Vol (10d)42.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—